IVF after 40

A woman’s reproductive lifespan begins with menarche in early adolescence and ends with the menopause. During this window, around 15% of couples encounter difficulty conceiving. In modern Western societies, increasing numbers of women begin trying for a first pregnancy in their late thirties or early forties, often as a consequence of professional choices.

Unfortunately, female fertility declines steeply with age. The rate of infertility rises from approximately 10% at age 34 to over 85% by age 44. It is therefore not surprising that around 14% of IVF cycles in Europe today are performed in women older than 40.

Does a woman’s age affect the live-birth rate after IVF?

The negative effect of age has been confirmed by every major IVF outcome registry. According to the most recent reports of the large international IVF registries (cycles 2020–2022), the live-birth rate per embryo transfer with autologous oocytes follows this declining trajectory: at ages 38–40 it ranges around 20–25%; at ages 41–42 it falls to approximately 10%; beyond age 42 it drops below 5%.

In parallel with the falling live-birth rate, the spontaneous miscarriage rate increases from roughly 25–30% at age 40 to over 50% after age 43. The principal driver of this dramatic deterioration is the rising frequency of chromosomal abnormalities (aneuploidies) in embryos.

How does age affect the outcome of IVF?

Two mechanisms account for the age-related decline. The primary one is oocyte quality: the frequency of chromosomal abnormalities in oocytes and embryos rises steeply after age 38. At age 40 around 50% of blastocyst-stage embryos are aneuploid; at age 44 the figure approaches 85%.

The secondary contributor is endometrial receptivity. Studies using donor oocytes show that the probability of clinical pregnancy remains relatively stable up to about age 45 of the recipient, indicating that the endometrium largely retains its receptive capacity. When donor oocytes are used, the live-birth rate per transfer in women over 40 is around 50% — substantially higher than any rate achievable with autologous oocytes in this age group.

How is ovarian reserve assessed before treatment?

Two tests are today the principal prognostic markers used before starting stimulation. AMH (anti-Müllerian hormone) is measured by a blood test on any day of the cycle and reflects the population of small follicles in the ovary. The antral follicle count (AFC) is measured by ultrasound during the first days of the cycle. AMH values below 1 ng/ml or AFC below 5–7 indicate likely poor response to stimulation. FSH, combined with oestradiol, provides additional information but is a less reliable marker.

Is there an upper age limit beyond which IVF is no longer a realistic option?

The data from all the large registries converge on the same answer: after age 45, the probability of live birth with autologous oocytes is essentially zero. For women in this age group, oocyte donation is the realistic route to pregnancy.

IVF with autologous oocytes in women older than 45 does not offer a realistic chance of live birth.

Which factors predict success in women older than 40?

Beyond age itself, the most reliable predictors of IVF success in women over 40 are the number of oocytes retrieved and the number of high-quality embryos available. In a review of 1,114 cycles, the live-birth rate was significantly lower when fewer than 6 oocytes were retrieved compared with 6 or more (5.9% vs 15.0%).

The presence of surplus embryos suitable for cryopreservation reflects a qualitatively superior ovarian response and constitutes a favourable prognostic sign. Women aged 40–43 with an adequate ovarian response have a markedly better prognosis than their peers with a poor response.

What is the role of preimplantation genetic testing (PGT-A) in women older than 40?

Given the steep rise in aneuploidy with age, preimplantation genetic testing for aneuploidies (PGT-A) is used to select only euploid embryos for transfer. In women over 40, PGT-A increases the live-birth rate per embryo transfer, reduces the miscarriage rate, and shortens the time to pregnancy.

Important caveat: PGT-A does not increase the cumulative live-birth rate per stimulation cycle — it simply triages the same embryos so that the one most likely to result in pregnancy is transferred first. The decision is individualised on the basis of the number of available embryos, the woman’s age, and the cost of the test.

How many embryos should be transferred?

In earlier years, transfer of multiple embryos was recommended in women over 40 to maximise the pregnancy rate. Current guidelines from the major international reproductive medicine societies recommend transfer of a single euploid embryo (following PGT-A) as the preferred option at any age. In the absence of PGT-A, transfer of a single high-quality blastocyst remains the preferred option; transfer of two embryos may be considered selectively in women over 40 with a history of previous failed cycles.

Transferring multiple embryos increases the risk of twin or higher-order multiple pregnancy, which in women over 40 carries a significantly elevated risk of preterm birth, gestational diabetes, preeclampsia, and other obstetric complications — risks already elevated by advanced maternal age.

Is natural-cycle IVF an option in women over 40?

Natural-cycle IVF (without ovarian stimulation) has been proposed as an alternative for women with low ovarian reserve. However, live-birth rates per cycle are substantially lower than with conventional stimulation. In women aged 44–47, realistic chances of success remain extremely limited regardless of the method used.

Which stimulation protocol is appropriate?

Earlier studies suggested that the long agonist protocol was advantageous in women over 40. Subsequent evidence, including the 2017 Cochrane meta-analysis, has shown that the GnRH antagonist protocol delivers an equivalent live-birth rate with significantly lower risk of ovarian hyperstimulation and a shorter treatment duration. The antagonist protocol is therefore preferred today in women over 40, with the gonadotrophin dose individualised based on AMH and AFC.

Summary.
A woman’s age remains the single most important prognostic factor for IVF success. In women aged 40–44, IVF with autologous oocytes continues to offer a realistic chance of live birth, although multiple attempts are often required. Pre-treatment assessment of ovarian reserve with AMH and AFC, individualised stimulation, transfer of a single high-quality embryo (preferably euploid following PGT-A), and realistic counselling of the couple are the cornerstones of contemporary management. In women older than 45, IVF with autologous oocytes does not offer realistic odds; oocyte donation is the only dependable option.